Maxon Introduces Cinebench 2024
5.9.2023 16:06:00 EEST | Business Wire | Press release
Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists and creators of all types, is thrilled to announce the highly anticipated release of Cinebench 2024. This latest iteration of the industry-standard benchmarking software, which has been a cornerstone in computer performance evaluation for two decades, sets a new standard for performance evaluation, embracing cutting-edge technology to provide artists, designers, and creators with a more accurate and relevant representation of their hardware capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905630586/en/
Maxon Introduces Cinebench 2024: A New Standard for Performance Evaluation (Photo: Business Wire)
Redshift Rendering Engine Integration
Cinebench 2024 ushers in a new era by embracing the power of Redshift, Cinema 4D's default rendering engine. Unlike its predecessors, which utilized Cinema 4D's standard renderer, Cinebench 2024 utilizes the same render algorithms across both CPU and GPU implementations. This leap to the Redshift engine ensures that performance testing aligns seamlessly with the demands of modern creative workflows, delivering accurate and consistent results.
Dual Performance Evaluation: CPU and GPU
Cinebench 2024 reinstates GPU benchmarking, a feature absent from Cinebench for the past decade. The latest version not only evaluates CPU performance; it also provides insights into the GPU's capabilities, reflecting the evolving technological landscape of creative software and workflows.
Wider Platform Compatibility
Cinebench 2024 is designed to accommodate a broader range of hardware configurations. It seamlessly supports x86/64 architecture (Intel/AMD) on Windows and macOS, as well as Arm64 architecture to extend its reach to Apple silicon on macOS and Snapdragon® compute silicon on Windows, ensuring compatibility with the latest advancements in hardware technology. Redshift GPU performance can be evaluated on systems with compatible Nvidia, AMD and Apple graphics processors.
Unified Benchmarking Scene
Cinebench 2024 streamlines the benchmarking process by utilizing a consistent scene file for both CPU and GPU testing. This innovation enables users to discern the advantages of leveraging Redshift GPU, providing a real-world glimpse into the benefits of harnessing cutting-edge graphics hardware for rendering tasks.
Revamped User Interface
Cinebench 2024 introduces a revamped user interface that enhances the user experience and showcases the incredible artistic endeavors achieved with the Redshift render engine in Cinema 4D. This dynamic interface serves as a testament to the potential of the Redshift engine while offering users a more intuitive and visually engaging experience.
Under-the-Hood Enhancements
Beyond the surface, Cinebench 2024 brings forth a host of performance-enhancing features. With a threefold increase in memory footprint compared to Cinebench R23, the software caters to the memory-intensive demands of modern projects. Moreover, a six-fold rise in computational effort and utilization of newer instruction sets ensures a benchmark that resonates with the complexity and sophistication of contemporary creative projects.
Unparalleled Performance Evaluation
It's crucial to note that Cinebench 2024 scores cannot be directly compared to those of its predecessor, Cinebench R23. With the incorporation of Redshift, a different rendering engine, larger memory footprint, and more complex scenes, Cinebench 2024 offers a distinctly enhanced and accurate evaluation of modern hardware capabilities.
Availability
Cinebench 2024 is immediately available for download starting today on the official Maxon website. Creatives, gamers and technology enthusiasts are invited to explore this groundbreaking benchmarking tool and experience firsthand the leap in performance evaluation that it offers.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.
Maxon’s team is composed of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905630586/en/
Contact information
Press Contact
Chloe Larby
Grithaus Agency
(e) chloe@grithaus.agency
(p) +44 7454 012045
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom